Novo CEO pressed by Senate to chop price ranges of obesity, diabetic issues medicines CEO Lars Fruergaard Jørgensen advised lawmakers the business would think about new talks with insurers with regards to the record rates of Wegovy and copyright when they pledge to maintain the medicines on their own formularies. https://kethek.com/